Can You Take Stelara with a Cancer History?
Stelara (ustekinumab) is contraindicated in patients with active cancer due to its immunosuppressive effects, which could promote tumor growth or recurrence. The prescribing information explicitly states: "USTEKINUMAB IS NOT RECOMMENDED IN PATIENTS WITH A KNOWN MALIGNANCY" and advises against use in those with a history of malignancy.[1] Physicians must weigh individual risks, but approval is rare without oncology clearance.
What Does the Label Say About Cancer Risks?
Stelara suppresses IL-12 and IL-23 cytokines, weakening immune surveillance against cancers. Clinical trials showed higher malignancy rates (0.7% vs. 0.2% in placebo) in psoriasis patients, including basal cell carcinoma and melanoma.[1] Post-marketing data reports additional cases, like non-melanoma skin cancers. The label requires screening for latent TB and malignancies before starting, with ongoing monitoring.[1]
How Do Doctors Decide for Past Cancer Patients?
Treatment hinges on cancer type, stage, time since remission, and current health. For example:
- Non-melanoma skin cancers or early-stage solid tumors in full remission (5+ years) might allow use after specialist review.
- Hematologic cancers, active disease, or recent diagnoses typically bar it.
Guidelines from the American College of Rheumatology recommend avoiding biologics like Stelara in active malignancy but permit case-by-case evaluation post-remission.[2] Always get an oncologist's input—self-assessment risks severe outcomes.
What Happens If You Start Stelara Anyway?
Immunosuppression raises recurrence odds; trials noted squamous cell carcinomas and lymphomas in users.[1] FDA warnings highlight increased infection and cancer risks with long-term use. Discontinue if malignancy develops, per label.[1]
Alternatives for Inflammatory Conditions with Cancer History?
Safer options depend on your condition (e.g., psoriasis, Crohn's):
- Methotrexate or apremilast (less immunosuppressive).
- Other biologics like etanercept (TNF inhibitors) sometimes used post-remission, but similar cautions apply.
- Consult your doctor for personalized swaps—e.g., Skyrizi (risankizumab) has a comparable but monitored cancer profile.[3]
Consult a healthcare provider before any changes; this is not medical advice.
[1] Stelara Prescribing Information (FDA.gov)
[2] ACR Guidelines on Biologic Use in Rheumatic Diseases (rheumatology.org)
[3] Skyrizi Prescribing Information (FDA.gov)